STAT3 and cancer: Additionally, DDSs integrated with anti‐STAT3 inhibitors have demonstrated superior outcomes in cancer treatment compared with the use of inhibitors alone, highlighting the potential of NP‐based approaches to enhance drug targeting, reduce systemic toxicity, and improve overall therapeutic efficacy [308].